|
New Hepatitis C Antiviral CB5300 Identified by Canopus BioPharma Researchers to Enter Clinical Trial Assessment
Canopus BioPharma, Inc., a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer and addiction, announced that CB5300, its new antiviral drug candidate for treatment of Hepatitis C, will be entering into clinical trial assessment following successful in-vitro screening. |
Register Now
Archives